GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Zhong Yuan Bio-Technology Holdings Ltd (OTCPK:ZHYBF) » Definitions » EBITDA per Share

Zhong Yuan Bio-Technology Holdings (Zhong Yuan Bio-Technology Holdings) EBITDA per Share : $-0.02 (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Zhong Yuan Bio-Technology Holdings EBITDA per Share?

Zhong Yuan Bio-Technology Holdings's EBITDA per Share for the six months ended in Sep. 2023 was $0.03. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.02.

During the past 3 years, the average EBITDA per Share Growth Rate was -179.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Zhong Yuan Bio-Technology Holdings's EBITDA per Share or its related term are showing as below:

ZHYBF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -179.1   Med: -102.55   Max: -26
Current: -179.1

During the past 8 years, the highest 3-Year average EBITDA per Share Growth Rate of Zhong Yuan Bio-Technology Holdings was -26.00% per year. The lowest was -179.10% per year. And the median was -102.55% per year.

ZHYBF's 3-Year EBITDA Growth Rate is ranked worse than
99.87% of 1564 companies
in the Consumer Packaged Goods industry
Industry Median: 6.7 vs ZHYBF: -179.10

Zhong Yuan Bio-Technology Holdings's EBITDA for the six months ended in Sep. 2023 was $0.49 Mil.

During the past 3 years, the average EBITDA Growth Rate was -191.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 8 years, the highest 3-Year average EBITDA Growth Rate of Zhong Yuan Bio-Technology Holdings was -31.90% per year. The lowest was -191.90% per year. And the median was -111.90% per year.


Zhong Yuan Bio-Technology Holdings EBITDA per Share Historical Data

The historical data trend for Zhong Yuan Bio-Technology Holdings's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhong Yuan Bio-Technology Holdings EBITDA per Share Chart

Zhong Yuan Bio-Technology Holdings Annual Data
Trend Dec16 Dec17 Dec18 Mar19 Mar20 Mar21 Mar22 Mar23
EBITDA per Share
Get a 7-Day Free Trial 0.02 - 0.01 -0.03 -0.09

Zhong Yuan Bio-Technology Holdings Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.03 -0.06 -0.04 0.03

Zhong Yuan Bio-Technology Holdings EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Zhong Yuan Bio-Technology Holdings's EBITDA per Share for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA per Share(A: Mar. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-1.542/17.666
=-0.09

Zhong Yuan Bio-Technology Holdings's EBITDA per Share for the quarter that ended in Sep. 2023 is calculated as

EBITDA per Share(Q: Sep. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=0.486/17.686
=0.03

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhong Yuan Bio-Technology Holdings  (OTCPK:ZHYBF) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Zhong Yuan Bio-Technology Holdings EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Zhong Yuan Bio-Technology Holdings's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhong Yuan Bio-Technology Holdings (Zhong Yuan Bio-Technology Holdings) Business Description

Traded in Other Exchanges
N/A
Address
28 Queen’s Road East, Suite 901, Tesbury Centre, Wanchai, Hong Kong, HKG
Zhong Yuan Bio-Technology Holdings Ltd is engaged in the business of developing and marketing nervonic acid-based health supplements and sales of acer truncatum seedlings. The company has two reportable segments such as sales of health care supplements and technical supporting services. The company generates its revenue primarily from the sales of health care supplements.
Executives
Tingting Chang director, 10 percent owner, officer: CEO RM 1002, 10THFL, LONG HU FUTURE OFFICE, NO. 1 EAST SHI LI PU ROAD, CHAO YANG DISTRICT, BEIJING F4 100024
James M Cassidy director, 10 percent owner, officer: president,secretary,treasurer 215 APOLENA AVENUE, NEWPORT BEACH CA 92662
James K Mckillop director, 10 percent owner, officer: Vice President 9454 WILSHIRE BOULEVARD, SUITE 612, BEVERLY HILLS CA 90212

Zhong Yuan Bio-Technology Holdings (Zhong Yuan Bio-Technology Holdings) Headlines

No Headlines